Abstract The experimental characterisation of electrospun poly(lactic acid) (PLA):poly(e-caprolactone) (PCL) as drug carriers, at five blend ratios from 1:0, 3:1, 1:1, 1:3 and 0:1, was holistically investigated in terms of their morphological structures, crystallinity levels and thermal properties. A widely used antibiotic tetracycline hydrochloride (TCH) was loaded to prepared fibrous mats at TCH concentrations of 1 and 5 wt%. The additional TCH into PLA:PCL better facilitates the reduction of fibre diameter than polymer blends. Increasing the TCH concentration from 1 to 5 wt% was found to result in only a modest decrease in the crystallinity level, but a significant increase in the crystallisation temperature (T c ) for PLA within PLA:PCL blends. The infrared spectra of fibre mats confirm the successful TCH encapsulation into fibrous networks. The first order and Zeng models for drug release kinetics were in better agreement with experimental release data, indicating the release acceleration of TCH with increasing its concentration. In a typical case of PLA:PCL (1:1) loaded with 5 wt% TCH, the fibre mats apparently demonstrate more wrinkled and floppy structures and increased fibre diameters and decreased inter-fibrous spaces after 7-day in vitro fibre degradation, as opposed to those obtained after 3-h degradation.
Introduction
With a rapid growth in nanotechnology and nanomaterials ranging from health science and engineering, electrospinning becomes an efficient and versatile processing method to produce continuous ultrafine fibres on micro/nanoscaled level from prepared polymer solution with cost-competitiveness [1] [2] [3] [4] [5] [6] [7] [8] . Its application in drug release system is of particular interest with several advantages over other dosage methods. These include the easy incorporation of therapeutic compounds into electrospun polymer fibre carriers, well-tailored release profile by controlling the morphology, porosity and compositions of nanofibrous structures [9, 10] , as well as more efficient drug release and mass transfer due to small fibre diameter, high surface areas and porous structures [11, 12] .
Thakur et al. [13] successfully fabricated dual drug release electrospun scaffolds, consisting of lidocaine and mupirocin, from a poly-L-lactic acid (PLLA) solution. The release kinetics was found to be altered by at least one drug, and dual spinneret technique was confirmed to be the preferred fabrication method for prototyping wound healing device. Meng et al. [14] studied both aligned and randomly oriented poly(D,L-lactide-co-glycolide) (PLGA)/ chitosan nanofibrous scaffolds to release model drug fenbufen (FBF). With increasing the chitosan content, the drug release rate also increased due to the enhancement of hydrophilicity of PLGA/chitosan composite scaffolds. The nanofibre arrangement was shown to impact the release behaviour with the lower release rate taking place in aligned nanofibrous structures as opposed to randomly oriented counterparts. Katti et al. [15] initially optimised the electrospinning parameters such as needle diameter, polymer solution concentration and voltage per unit length to understand their effects on the morphology and diameter of poly(lactide-co-glycolide) (PLAGA) nanofibres. At the later stage, a broad-spectrum antibiotic cefazolin was used, which shows that PLAGA nanofibre scaffolds could be a potential carrier for effective antibiotic delivery systems targeting the wound treatments. Luong-Van et al. [16] showcased the use of electrospun poly(e-caprolactone) (PCL) as a promising carrier candidate for heparin delivery to the site of vascular injury. This study found that about the half of the encapsulated heparin was released by diffusional control from electrospun heparin/PCL fibres after 14 days. There was no inflammatory response induced from such fibres in macrophage cells in vitro. Additionally, the proliferation of vascular smooth muscle cell (VSMC) in culture was effectively prevented by heparin. Kenawy et al. [17] evaluated electrospun fibres based on PCL as a biodegradable polymer and polyurethane (PU) as a non-biodegradable polymer to deliver the anti-inflammatory drug ketoprofen. Their results indicate that the similar release rates were detected irrespective of used polymer or blend types. Nonetheless, PCL/PU blends demonstrated improved visual mechanical properties. Taepaiboon et al. [18] developed electrospun poly(vinyl alcohol) (PVA) fibre mats as drug carriers for transdermal drug delivery system. Four types of non-steroidal anti-inflammatory drug with varying water solubility property, i.e. sodium salicylate (freely soluble in water), diclofenac sodium (sparingly soluble in water), naproxen (NAP), and indomethacin (IND) (both insoluble in water), were selected as model drugs. Both release rate and total amount of released drugs from PVA fibre mats were found to be dependent upon the molecular weight of the model drugs. Increasing molecular weight of drugs appeared to decrease both the rate of total release amount. Besides, in comparison to drug-loaded ascast films, PVA mats presented much better release characteristic.
PLA can be either semi-crystalline or amorphous biopolymers, depending on the relative ratio of PLA backbone chains produced in the chemical synthesis. Its attractive material features consist of easy processability with the ability to be dissolved in common solvents [19] , as well as good environmental sustainability and biocompatibility [20] . Nonetheless, PLA biodegradation can be harmful to local tissues [21] owing to its low pH value [22] . On the other hand, PCL, as a hydrophobic and semi-crystalline polymer [17] , possesses a crystallisable rubbery behaviour used for the enhancement of elasticity [23] . Moreover, PCL is also well known for its acceptable drug permeability and effective biocompatibility [24] . The PCL degradation cannot form a local acidic environment, which as the main advantage along with its moderately low cost allows PCL to be a good polymer candidate for biomedical applications [16, 17] . In comparison, PCL often undergoes much slow degradation process and appears to be less harmful to local tissues as opposed to PLA [24] .
Polymer blending represents a very essential polymer processing technique in order to develop or adjust the physicochemical properties of polymeric materials for the benefit of using mutual material merits [25] . Sometimes, generated polymer blends present totally different or unique properties from those of individual virgin polymers [26] . The simplicity of blend preparation enables to achieve greatly improved material properties by appropriate combination of basic polymeric components [27] .
Nowadays, the use of biopolymers as a carrier for drug delivery systems has gained the great popularity due to promoted healing effectiveness and decrease in medical side-effects resulting from their non-toxicity [28] . Therapeutic drugs can be easily loaded into polymer fibre mats by means of electrospinning technique. The composition and morphological structures of such mats, as altered by the appropriate material fabrication, have remarkable impact on the drug release control [24] . Tetracycline hydrochloride (TCH) is a hydrophilic antibiotic used for the healing and avoidance of bacterial infections taking place in the burns, cuts and surgeries for various wound healing purposes.
The objective of this study is to evaluate the effect of PLA:PCL blend ratio on the fabrication, structural analysis and material characterisation of TCH-loaded PLA:PCL fibre mats, and further to produce a new carrier system for the effective drug delivery. The mathematical modelling for drug release kinetics has also been implemented in good accordance with the experimental release data.
Experimental details
Materials PLA 3051D pellets with the molecular weight of 93500 g/mol was supplied by NatureWorks, USA. As-received PCL with the molecular weight of 80000 g/mol, TCH (C 22 H 24 N 2 O 8 ÁHCl and molecular weight of 480.9 g/mol), phosphate buffer solution (PBS), chloroform and methanol solvents were purchased from Sigma-Aldrich Ltd, Australia.
Material fabrication via electrospinning
Prior to the electrospinning process, 8 wt%/v PLA was initially mixed with 9 wt%/v PCL at five different blend ratios of 1:0, 3:1, 1:1, 1:3 and 0:1 using chloroform and methanol solvents (2:1 volume ratio). Subsequently, 1 and 5 wt% TCH drugs were dissolved in methanol and further added to PLA:PCL blend solutions, respectively. Those prepared solutions were separately transferred to a medically used 10-ml plastic syringe that were mounted on a Fusion 100 syringe pump (Chemyx Inc., Stafford, TX USA), and also attached to a metallic needle with an inner diameter of 0.584 mm. The whole electrospinning process was carried out with a solution flow rate of 2 ml/h and high voltage settings between 25 and 28 kV at 24°C. A mesh ground collector covered with aluminium foils was employed at a needle-to-collector distance of 13 cm to receive the electrospun fibre mats. The thickness of fibre mats was measured in range of 300-450 lm by a micrometer.
In vitro drug release study
The TCH-loaded fibre mats were cut in size of 2 9 2 cm and underwent a rotary shaker incubation (rotor speed: 100 rpm) at 37°C at a 20-ml PBS with pH 7.4. When the required incubation time is reached for the designated drug release, the mat sample was further transferred to a 20-ml fresh buffer solution. About 11 incubations for each TCH concentration were made for obtaining drug release data from prepared fibre mats. Each incubation process was subjected to three repeated tests for data reproducibility. After this step, the released TCH amount in the buffer solution was determined accordingly.
In vitro biodegradation study
The fibre mats with the same size were measured with the initial mass m and transferred to a 15-ml PBS (pH 7.4). They were subsequently subjected to the rotary shaker incubation at a rotor speed of 100 rpm in a 15-ml PBS (pH 7.4) for the biodegradation study. The fibre mats were removed at each given incubation period and further washed in deionised water. A final mass m 1 of fibre mats was obtained after drying them under vacuum at 37°C. The total mass loss m% was determined accordingly in a simple expression below
Material characterisation
Two critical parameters of solution viscosity and electrical conductivity in electrospinning were measured with the aid of a Visco 88 portable viscometer, Malvern Instruments, UK and a WP-81 Waterproof Conductivity Meter, TPS, Australia, respectively.
The fibre morphology was investigated by means of an EVO 40XVP scanning electron microscope (SEM), Germany, at an accelerating voltage of 5 kV. Fibre mat samples were subjected to sputter coating with platinum prior to the SEM evaluation. The embedded Zeiss smart SEM software was utilised for the on-screen measurements of individual fibre diameters. The average fibre diameters were calculated based on sample measurements from a minimum 150 fibres in multiple-scanned SEM images (i.e. at a rate of over 15 fibres per image).
Wide angle X-ray diffraction (XRD) analysis was undertaken using a Bruker Discover 8 X-ray diffractometer, Germany, which was in operation at 40 kV and 40 mA. The Cu-Ka radiation (wave length k = 1.54 Å for a Cu target) was monochromatised with graphite sample monochromators in a 2h range from 7.5°to 40°with a scanning rate of 0.016-0.02°/s. The crystallinity level was determined by applying the area integration method [29, 30] to XRD intensity data over the range of 2h from 8°to 27°.
Thermal analysis based on differential scanning calorimetry (DSC) was carried out using a DSC6000 Perkin Elmer, USA, with a cryofill liquid nitrogen cooling system. About a 10-mg fibre mat was sealed in an aluminium crucible and subsequently underwent heating-cooling cycles from -90 to 200°C with a ramp rate of 10°C/min. The DSC thermograms and associated thermal parameters such as glass transition temperature (T g ), crystallisation temperature (T c ) as well as melting temperature (T m ) were obtained from the first heating scan.
Fourier transform infrared spectroscopy (FTIR) was performed in a Spectrum 100 FTIR Spectrometer Perkin Elmer, Japan. The resulting spectra were captured from 4000 to 550 cm -1 with 4 cm -1 resolution on the basis of an attenuated total reflectance (ATR) technique [31] .
The TCH amount in the PBS for in vitro drug release study was determined from a UV-Vis spectrophotometer Jasco V-67, USA, at a wavelength of 360 nm. The drug release curves against the release time were acquired for understanding the release kinetics of TCH from prepared fibre mats.
Mathematical models for drug release kinetics
The drug release experimental data can be fitted to some release kinetic models [32, 33] not only to assess the transport of drug molecules, but also to facilitate the understanding of drug-carrier interaction whose mechanism can dictate the final drug release profile [24] . As a result, such direct interaction may lower the drug solubility, and thus retard their release from carriers [34] . This study focuses on five generally used kinetic models to interpret the drug release mechanism, namely zero order, first order, Higuchi, Ritger-Peppas and Zeng models [32] [33] [34] as detailed in the following subsections.
Zero order model
The zero order model is employed to a drug delivery system in which the drug release rate is independent of drug concentration. Its empirical equation [35] can be described as
where M t , M ? and K 0 are the absolute cumulative amount by mass of drug released at time t and infinite time, and the zero order release constant, respectively. The ratio M t /M ? is denoted as the cumulative release amount in percentage [32] . Apparently, M t /M ? is linearly proportional to the time t for zero order kinetics, which is an ideal method to achieve a prolonged pharmacological action. Zero order model can be implemented in the determination of drug dissolution from a widespread range of modified release dosage forms including matrix, tablet with low soluble dugs, coated tablets and capsules, as well as osmotic systems [36, 37] .
First order model
The first order model kinetics was initially employed by Gibaldi and Feldman [38] in 1967 and later by Wagner [39] in 1969. The release in the drug delivery system is usually concentration dependent. The first order equation can be in a derived mathematical form [33, 40] for the released drug in an aqueous phase [31] below
in which K 1 is the first order release constant.
Higuchi model
Higuchi developed important mathematical models to study the release of water soluble and low soluble drugs loaded in semi-solid and solid matrices [41, 42] . The initial attempt was based on the validity of Higuchi model only for a planar system, which subsequently considered different geometries and matrix characteristics even for the porous structures [42] [43] [44] [45] [46] . The equation of Higuchi model [33, 40, 47] can be simplified as
where K H is the Higuchi kinetic constant that reflects the design variables in the drug delivery system. In Higuchi model, the fraction of drug released is proportional to the square root of time. Higuchi model is often used under the following assumptions [47] : (i) much higher initial drug concentration than the solubility of the drug in the system, (ii) one-dimensional drug diffusion with the negligibility of edge effects, (iii) fine state of suspended drug in which the particle diameter is much smaller than the thickness of the system, (iv) ignored dissolution and swelling of drug carrier, (v) constant drug diffusivity and (vi) maintained perfect sink conditions.
Ritger-Peppas model
Ritger and Peppas established a simple exponential relation to investigate both Fickian and non-Fickian drug release in swelling and non-swelling polymeric delivery systems [35, 48] . Such mathematical equation for Ritger-Peppas model is given by
where K R is the Ritger-Peppas kinetic constant that incorporates structural and geometric characteristics of the macromolecular network system and the drug. n is the diffusion exponent indicating the transport mechanism through the polymer. Base on different ranges of n values in Ritger-Peppas model, the drug release can be classified as Fickian diffusion release from non-swellable matrix (n B 0.5), as well as non-Fickian release in both diffusion and erosion-controlled mechanisms (0.5 \ n \ 1) [35, 48] . Clearly, when n = 1, the simplified equation from RitgerPeppas model becomes that of first order model in a special case.
Zeng model
Zeng et al. [34] recently developed a three-parameter model with the close-form analytical solution to consider the reversible drug-carrier interaction and first order drug release from liposomes. The equation for Zeng model is relatively complex as given by
and
In Eq. (6), K on is the rate constant of association for nondispersed drug molecules in the system that need to be disassociated from carriers prior to release. Conversely, K off is the rate constant of disassociation accordingly and K S is a constant proportional to the surface-to-volume ratio of carriers for the enhancement of drug release. In addition, DG is the free energy difference between the free and bound state, k B is the Boltzmann's constant and T is the absolute temperature that is assumed to be 300 K in Eq. (7). K off , K S and DG are three critical parameters in Zeng model to describe the effect of cumulative drug release.
Results and discussion
Effect of blend ratios and loaded drug on fibre morphology
As illustrated in Figs. 1 and 2 , electrospun fibres produced from dissolved PLA in chloroform and methanol have the average fibre diameter of 510 nm. In such PLA-based system, when increasing the ratio of PLA to PCL up to 3:1, a relatively large fibre diameter at 562 nm is achieved with the intermediate quality due to the non-uniform morphology, Fig. 1b . A further amount increase of PCL to 1:1 led to more uniform fibre structure with an average diameter of 689 nm. Such increasing trend for the fibre diameter continued when the ratio of PLA to PCL became (1:3) and (0:1), resulting in the fibre diameter of 742 and 786 nm, respectively. Figure 3 illustrates the measured viscosities of different PLA:PCL blends. It has been found that viscosities of blend solutions significantly increase from 68 (PLA solution only) to 138 cP in a linearly monotonic manner by increasing the quantity of PCL in the PLA:PCL system. The PCL solution offers the highest viscosity of 182 cP among all prepared solutions. According to our previous work [3] , fibre diameter is dominantly influenced by the solution viscosity. As is well understood, in viscous solutions, there are a greater number of entanglements per polymer chain which is a prerequisite for the formation of a stable jet, and this phenomenon also compensates for the detrimental effect of increased surface tension, resulting in the jet shrinkage [49] .
On the other hand, the loaded 1 and 5 wt% TCH drug into PLA:PCL (1:1) system further reduce the fibre diameter to 364 and 302 nm, respectively, Fig. 2 . This result can be attributed to the remarkable enhancement of electrical conductivity from 31 to 90 ls/cm when the TCH concentration increases from 1 to 5 wt%, as opposed to 1 ls/cm for the solution without TCH, Table 1 . The increase of electrical conductivity inevitably produces more electric charges that are carried by the electrospinning jet so that resulting fibres can be further elongated with smaller diameter [50, 51] . Moreover, the replacement of partial polymers of either PLA or PCL (with far higher molecular weights) by very low molecular weight TCH inevitably decreases the solution viscosity, thus resulting in the smaller fibre diameters depicted in Fig. 2 .
Crystallinity and thermal properties
The effect of the TCH concentration on the degree of crystallinity and crystalline structures of electrospun fibre samples was investigated by an XRD examination. All the blend samples demonstrate two distinct diffraction peaks at 2h = 20.11°and 23.2°similar to those strong peaks from neat PCL fibres, which correspond to the crystal planes (101) and (200), respectively, Fig. 4 . Their peak positions have not been greatly altered, indicating that the loaded TCH has minor impact on the crystalline structures of electrospun PLA:PCL fibres. As a result, TCH drug is most likely to be dispersed in an amorphous state in PLA:PCL fibrous structures. Besides, the solvent evaporation may be accelerated due to the large fibre surface area and small fibre diameters generated in the electrospinning process. This phenomenon can provide a short period for the drug formation and recrystallisation of preferred configuration in amorphous state [52] . PCL fibres possess distinct highintensity XRD peaks with a higher degree of crystallinity (X c ) about 68 %, whilst PLA fibres indicate dominant amorphous phases (as seen from almost invisible peaks in the inserted diagram in Fig. 4) with the X c value of only 13 %, Table 2 . Even though the peak intensities for PLA:PCL blends are between those of PLA and PCL fibres, a higher PCL concentration from their blend ratio of 3:1 to 1:1 expectedly leads to the enhanced peak intensities that may contribute to the increased X c . Irrespective of the TCH drug loading, it has been found that the X c increases from 37 % for PLA:PCL (3:1) to 43-46 % for PLA:PCL (1:1).
The DSC results of electrospun PLA, PCL and PLA:PCL fibres loaded with or without TCH drug are shown in Fig. 5 and Table 2 . The glass transition temperature (T g ) and melting temperature (T m ) of PCL moderately decrease when increasing the TCH concentration from 0 to 5 wt%. However, the blend ratio and the use of TCH have little impact on the T m of PLA within polymer blends, which is in range of 151-152°C (but \157°C for PLA fibres). In principle, short chains of TCH molecules cause their decreased packing density, and this facilitates the chain mobility leading to the lower T g of PCL. The loaded TCH to PLA:PCL (1:1) shows an insignificant change of crystallisation temperature (T c ) at 1 wt% concentration when compared to PLA:PCL (1:1) and PLA:PCL (3:1). At the TCH concentration of 5 wt%, T c underwent a drastic increase at over 99°C as opposed to 81°C of PLA within PLA:PCL (1:1) and 87°C for PLA fibres. This result suggests that low molecular weight TCH with a higher concentration of 5 wt% may hinder the cold crystallisation process of PLA, which plays an anti-nucleating agent role. Initially two carbonyl stretching (C=O) bands are assigned to 1724 cm -1 for PCL and 1758 cm -1 for PLA in electrospun PLA:PCL nanofibres; whereas the bands located at 2866 cm -1 (PLA component) and 2944 cm -1 (PCL component) are in description of C-H stretching. Furthermore, the peaks designated at 1457 and 1366 cm -1 specify a C-H deformation of PLA. It has also been found that many peaks representing C-C and C-O stretching are among the range from 1240 to 840 cm -1 for PLA and PCL. When the blend ratio of PLA:PCL increases from 1:1 to 3:1 with a higher amount of PLA, carbonyl stretching (C=O) bands at 1758 cm -1 for PLA become more prominent. For TCH-loaded PLA:PCL counterparts, despite the band shifting, two weak bands at 1614 and 1581 cm -1 have been observed for PLA:PCL (1:1) loaded with 5 wt% TCH, which are assigned to C=O stretching in ring A and C=O stretching in ring C, respectively, in good accordance Calculations were repeated for three sets of samples. The standard deviation for the T g , T c and T m values was \0.5°C a Calculate from XRD data with those assigned to TCH drug alone. This finding confirms the successful encapsulation of TCH into PLA:PCL blends. Such allocated bands appear to be quite vague for 1 wt% TCH-loaded PLA:PCL (1:1), which is most likely to arise from the use of low TCH concentration.
In vitro drug release
As mentioned earlier, a balanced level of crystallinity can be achieved in PLA:PCL (1:1) blend system since PCL with its high level of crystallinity restricts the mobility of drug molecules to make them stay around the fibre surfaces, while PLA with relatively low crystallinity can accelerate the fibre degradation. Typical TCH release profiles obtained from electrospun PLA:PCL (1:1) nanofibres loaded with 1 and 5 wt% TCH are presented in Fig. 7 . Similarly, both material samples indicate the fast drug release performance. In the initial 20 min, 44 % drug was released from PLA:PCL (1:1)/ 1 wt% TCH samples in contrast with 56 % from PLA:PCL (1:1)/5 wt% TCH. In the first 2 h, this release increases up to 59 and 64 % for 1 and 5 wt% TCH-loaded samples, respectively. This drastic release step is followed by a steady release in the remaining 10-day release tests. Such a fast release is associated with the great tendency of TCH drug molecules located on the surface of electrospun fibrous structures in that the fast evaporation of solvents and high ionic interactions generally occur in the electrospinning process. The faster release of TCH, when 5 wt% TCH was added to PLA:PCL blends, can result from the moving trend of dissolved TCH to the nanofibre surface over the electrospinning period. This movement accelerates the drug release rate compared with that for a low TCH concentration at 1 wt%. Increasing the TCH concentration in PLA:PCL blends leads to a decrease of crystallinity level for PLA:PCL as shown in Table 2 . Since drug release takes place initially from the amorphous regions [16] , it is also plausible to assume that TCH molecules tend to accumulate in the amorphous regions in view of little changes in the crystalline structures of PLA:PCL, Fig. 4 . As a result, the higher amount of TCH may result in a faster drug release rate from these regions. Our fabricated fibrous mats in this study provide a drug release profile with biomaterial and bioactive structures. They may become good carrier candidates to be employed in a range of wound healing application, as well as for the infective prevention after surgery with the requirement of fast drug release.
Release kinetics
The release kinetics of TCH drug is investigated by fitting five aforementioned mathematical models to the release Table 3 . The first order and Zeng models have better agreement with the release data with higher R 2 values at 0.889 and 0.948 for 1 % TCHloaded fibre mats as well as 0.930 and 0.975 for 5 % TCHloaded counterparts, respectively. The better fitting with the first order model may confirm the dependent effect of drug release upon the drug concentration and used carriers. On the other hand, according to Zeng model, the diffusion process and interaction between PLA:PCL blends and TCH also have significant impact on the drug release. When the TCH concentration increases from 1 to 5 wt%, DG as a critical parameter also increases from 1.47 9 10 -21 to 2.49 9 10 -21 J, which suggests the increase of TCH release and diffusivity owing to the greater amount of free TCH molecules on the PLA:PCL nanofibre surfaces. Furthermore, the other important parameter K S increased from 5.127 to 8.343 h -1 , indicating that the pore size becomes much larger when the TCH concentration increases. The variations in the fitted model parameters, especially DG and K S , are consistent with the previous interpretations of the drug release results.
In vitro biodegradation
Due to the vague bands for 1 wt% TCH-loaded PLA:PCL (1:1) in FTIR results mentioned earlier in Fig. 6 , the biodegradation behaviour is characterised in Table 4 , based solely on PLA:PCL nanofibres with the relatively high TCH concentration (i.e. PLA:PCL (1:1)/5 % TCH). After the degradation in PBS for the first 3-12 h, the mass loss of nanofibre mats is quite minimal (\0.81 %). When the degradation time increases up to 336 h, the mass loss shows an insignificant increase of only 6.30 %. This result can be explained partially by the semi-crystalline characteristic of PCL to preclude its degradation in a buffer solution [53] . In fact, in the absence of a biocatalyst, very little PCL degradation has been previously found in PBS [54, 55] . Figure 9 demonstrates the change of morphological structures in such nanofibre mats after being immersed in PBS over a two-week period. Nanofibres appear to be squashed to a great extent with the time, resulting in increased fibre diameters and decreased inter-fibre spaces after 7 days. More wrinkled structures have been observed after 7 days as opposed to those for the 3 h degradation. The degradation could initially take place in the amorphous Zero order model K 0 = 0.0017 K 0 = 0.0015
Ritger-Peppas model region of PLA:PCL nanofibres, and then around the crystalline area [56, 57] . In case of PLA component within PLA:PCL blends, nanofibre degradation in PBS tends to be heterogeneous. The degradation of nanofibre surfaces may be slower than that in the core areas where carboxylic acid groups exist by ester hydrolysis [58] . However, the swelling of nanofibres increases since TCH molecules, prevalently located on the nanofibre surfaces according to previous in vitro drug release study, would be flushed out faster than those confined inside fibrous structures. Consequently, more buffer solution penetrates through channels generated by the released TCH (Fig. 9) .
Conclusion
This investigation concentrated on the analysis of structure and morphological properties of electrospun PLA:PCL using different blend ratios and with/without the TCH drug. The fibre diameters were significantly reduced when loaded with 1 and 5 wt% TCH into PLA:PCL. The degree of crystallinity of PLA:PCL was enhanced from 37 to 46 % with decreasing the blend ratio from 3:1 to 1:1 accordingly. The use of TCH loaded to PLA:PCL (1:1) offered the moderate decreases of degree of crystallinity, (T g ) and T m of PCL by increasing TCH concentration from 0 to 5 wt%; whereas the T c of PLA within PLA:PCL blends increased remarkably, especially at the TCH concentration of 5 wt%, implying the anti-nucleating agent role of TCH to hinder the cold crystallisation of PLA. The infrared spectra of electrospun PLA:PCL nanofibres proved the successful encapsulation of TCH into the nanofibres. The release of TCH drug was found to be accelerated by increasing the TCH concentration. The overall fast drug release performance is manifested, which suggests its main applications for wound healing and quick surgery infective protection. In terms of understanding the release kinetics, release data were better fitted with the first order and Zeng models. Small mass loss of only 6.30 % was observed at the degradation time of 336 h for PLA:PCL (1:1)/5 wt% TCH. However, geometric changes of degraded nanofibres such as squashed fibres with increase diameters and decreased inter-fibre spaces were clearly shown after 7 days of degradation. 
